A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Wagner, 2010, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, CD004064 Wesolowski, 2009, Is there a role for second-line chemotherapy in advanced gastric cancer?, Lancet Oncol, 10, 903, 10.1016/S1470-2045(09)70136-6 Lordick, 2012, Gastrointestinal cancer: salvage chemotherapy in gastric cancer—more than a straw?, Nat Rev Clin Oncol, 9, 312, 10.1038/nrclinonc.2012.76 Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 Koizumi, 2008, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial, Lancet Oncol, 9, 215, 10.1016/S1470-2045(08)70035-4 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002 Kang, 2012, Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone, J Clin Oncol, 30, 1513, 10.1200/JCO.2011.39.4585 Ueda, 2012, Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial, ASCO Meeting Abstr, 30, 4002 Drummond, 2006, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res, 66, 3271, 10.1158/0008-5472.CAN-05-4007 Chen, 2008, Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients, J Clin Oncol, 29, 26 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Chen, 2012, Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer after first-line oxaliplatin-based chemotherapy, J Clin Oncol, 30 Chabot, 1995, Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials, Ann Oncol, 6, 141, 10.1093/oxfordjournals.annonc.a059109 Chabot, 1997, Clinical pharmacokinetics of irinotecan, Clin Pharmacokinet, 33, 245, 10.2165/00003088-199733040-00001 Ko, 2011, A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer, ASCO Meeting Abstr, 29, 4069 Egner, 1999, Group trial CPT-11 at 320 mg/m2 caused excessive toxicity in patients (pts) with advanced adenocarcinoma(ACA) of the stomach (S) or gastroesophageal junction (GJ): A North Central Cancer Treatment, Proc Am Soc Clin Oncol, 16, 207a Bang, 2002, Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial, Jpn J Clin Oncol, 32, 248, 10.1093/jjco/hyf057 de Jong, 2006, Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study, Oncologist, 11, 944, 10.1634/theoncologist.11-8-944 Cote, 2007, UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan, Clin Cancer Res, 13, 3269, 10.1158/1078-0432.CCR-06-2290 Toffoli, 2006, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer, J Clin Oncol, 24, 3061, 10.1200/JCO.2005.05.5400 Han, 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin, J Clin Oncol, 24, 2237, 10.1200/JCO.2005.03.0239 Jada, 2007, Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients, Cancer Sci, 98, 1461, 10.1111/j.1349-7006.2007.00541.x Minami, 2007, Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28, Pharmacogenet Genomics, 17, 497, 10.1097/FPC.0b013e328014341f Palomaki, 2009, Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review, Genet Med, 11, 21, 10.1097/GIM.0b013e31818efd77 Study of MM-398 with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer (NAPOLI 1)ClinicalTrials.gov Identifier: NCT01494506